InsiderPulse
Dashboard

IONS

Ionis Pharmaceuticals, Inc.

Health CareRussell 2000

Ionis Pharmaceuticals, Inc. insider trading

Ionis Pharmaceuticals, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Carlsbad, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent IONS insider transactions

11 insiders traded IONS on the open market between May 13, 2026 and Jul 31, 2026 — 2 purchases worth $1.1M, 19 sales worth $20M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
$1.1M
Sold
$20M

19 of 19 on a 10b5-1 plan

Net
−$19M
Insiders
11

Open-market purchases (code P) and sales (code S) from Ionis Pharmaceuticals, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every IONS Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

IONS insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 20 insiders traded IONS on the open market: 3 purchases worth $659K and 208 sales worth $191.9M, 154 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 172 sales ($184.9M), by 19 insiders.

QuarterBoughtSold
Q2 2026—−$26.5M26 sales · 23 on a plan
Q1 2026—−$82.8M67 sales · 46 on a plan
Q4 2025—−$32.9M38 sales · 35 on a plan
Q3 2025—−$42.6M41 sales · 37 on a plan
Q2 2025+$477.9K1 buy−$216.4K3 sales
Q1 2025—−$5.2M23 sales · 4 on a plan
Q4 2024+$181.1K2 buys−$811K4 sales · 3 on a plan
Q3 2024—−$829.8K6 sales · all on a plan
Largest purchase
+$477.9K of IONS by Hayden Michael R (Director) on May 01, 2025.
Largest sale
−$14.9M of IONS by Hougen Elizabeth L (EVP, Finance & CFO) on Mar 16, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Schneider Eugene10b5-1

    EVP, Chf Clinical Develop Ofcr

    −$2.1M

    Jun 26, 2026

    26,000 sh · $81.05

  • Baroldi Joseph10b5-1

    EVP, Chief Business Officer

    −$451.7K

    Jun 26, 2026

    5,635 sh · $80.16

  • Swayze Eric10b5-1

    EVP Research

    −$839.5K

    Jun 25, 2026

    10,602 sh · $79.18

  • Monia Brett P10b5-1

    Chief Executive Officer · Director

    −$1.1M

    Jun 24, 2026

    14,565 sh · $78.41

  • Kordasiewicz Holly B.10b5-1

    EVP, Chief Development Officer

    −$3M

    Jun 12, 2026

    41,004 sh · $73.09

  • Kordasiewicz Holly B.10b5-1

    EVP, Chief Development Officer

    −$1.5M

    Jun 12, 2026

    19,842 sh · $74.05

  • Monia Brett P10b5-1

    Chief Executive Officer · Director

    −$253.4K

    May 14, 2026

    3,220 sh · $78.68

  • Monia Brett P10b5-1

    Chief Executive Officer · Director

    −$102.7K

    May 13, 2026

    1,316 sh · $78.01

  • Loscalzo Joseph10b5-1

    Director

    −$4.5M

    May 04, 2026

    59,508 sh · $74.90

  • Loscalzo Joseph10b5-1

    Director

    −$1.3M

    May 04, 2026

    17,781 sh · $75.58

  • Klein Joseph III10b5-1

    Director

    −$636.7K

    May 01, 2026

    8,680 sh · $73.35

  • Klein Joseph III10b5-1

    Director

    −$106.5K

    May 01, 2026

    1,431 sh · $74.45

  • Baroldi Joseph10b5-1

    EVP, Chief Business Officer

    −$116.7K

    Apr 28, 2026

    1,626 sh · $71.79

  • Baroldi Joseph

    EVP, Chief Business Officer

    −$419K

    Apr 16, 2026

    5,619 sh · $74.56

  • Jenne Kyle

    EVP, Chf GL Pdt Str Ofcr

    −$368.5K

    Apr 16, 2026

    4,902 sh · $75.17

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Ionis Pharmaceuticals, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Carlsbad, CA
Incorporated in
CA
Listed on
Nasdaq
SEC Central Index Key
0000874015
Previously filed as
ISIS PHARMACEUTICALS INC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought IONS

What the stock actually did in the 90 days following each open-market purchase

Don't check IONS — let it ping you

Get told the moment an insider moves on IONS

Pro watches Ionis Pharmaceuticals, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add IONS to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track IONS on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read IONS insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

AXSMKRYSRAREFOLDACADPTCTMEDPDNLIVEEVTEMALKSAPLS
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are IONS insiders buying or selling?
Between May 13, 2026 and Jul 31, 2026, 11 Ionis Pharmaceuticals, Inc. insiders made 2 open-market purchases worth $1.1M and 19 sales worth $20M, a net sale of $19M. 19 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much IONS stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 20 Ionis Pharmaceuticals, Inc. insiders made 3 open-market purchases worth $659K and 208 sales worth $191.9M. 154 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 172 sales ($184.9M). The largest purchase was Hayden Michael R buying $477.9K on May 01, 2025. The largest sale was Hougen Elizabeth L selling $14.9M on Mar 16, 2026.
What was the largest recent IONS insider trade?
Monia Brett P (Chief Executive Officer · Director) sold $4M of IONS stock on Jun 26, 2026 at about $80.59 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy IONS shares?
The most recent open-market purchase on file is Hayden Michael R (Director) buying $258K on Jul 31, 2026. The largest purchase in the period was $800.7K by Hayden Michael R.
Where does IONS insider trading data come from?
From the Form 4 filings Ionis Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.